Status:

RECRUITING

A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Lead Sponsor:

AstraZeneca

Conditions:

Untreated Follicular Lymphoma

Eligibility:

All Genders

18-130 years

Phase:

PHASE3

Brief Summary

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the AZD0486 plus rituximab combination compared to Investigato...

Detailed Description

The study consists of 2 sequential parts. 1. Safety Run-in - this part will compare dose levels of AZD0486 in combination with rituximab in order to establish the RP3D. 2. Phase III - The Phase III p...

Eligibility Criteria

Inclusion

  • Participant must be at least 18 years of age, inclusive, at the time of signing the ICF.
  • Histologically confirmed diagnosis of classic FL per WHO 2022 classification
  • ECOG performance status of 0 to 2
  • No prior systemic lymphoma-directed therapy
  • Need for systemic treatment meeting at least 1 GELF criteria
  • FDG-avid and measurable disease
  • Stage II to IV and FLIPI 2-5 \[Phase III only\]
  • Adequate liver, hematological, renal and cardiac function.
  • The above is a summary, other inclusion criteria details may apply

Exclusion

  • Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologic transformation to high-grade/aggressive lymphoma
  • Contra-indication to BR, RCVP, and R-CHOP
  • Participants with or history of CNS lymphoma
  • Presence of \>5000 circulating lymphoma cells
  • Active or uncontrolled infection requiring systemic therapy and which places participant at unacceptable risk if he/she were to participate in the study
  • The above is a summary, other exclusion criteria details may apply

Key Trial Info

Start Date :

August 7 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 26 2031

Estimated Enrollment :

1015 Patients enrolled

Trial Details

Trial ID

NCT06549595

Start Date

August 7 2024

End Date

November 26 2031

Last Update

December 4 2025

Active Locations (121)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 31 (121 locations)

1

Research Site

Garran, Australia, 2605

2

Research Site

Heidelberg, Australia, 3084

3

Research Site

Macquarie University, Australia, 2109

4

Research Site

Nedlands, Australia, 6009